GILD
Price
$112.99
Change
+$0.28 (+0.25%)
Updated
Sep 3 closing price
Capitalization
140.2B
49 days until earnings call
GSK
Price
$39.36
Change
+$0.40 (+1.03%)
Updated
Sep 3 closing price
Capitalization
79.1B
55 days until earnings call
Interact to see
Advertisement

GILD vs GSK

Header iconGILD vs GSK Comparison
Open Charts GILD vs GSKBanner chart's image
Gilead Sciences
Price$112.99
Change+$0.28 (+0.25%)
Volume$4.55M
Capitalization140.2B
GSK
Price$39.36
Change+$0.40 (+1.03%)
Volume$4.21M
Capitalization79.1B
GILD vs GSK Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. GSK commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and GSK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (GILD: $112.99 vs. GSK: $39.36)
Brand notoriety: GILD: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 77% vs. GSK: 89%
Market capitalization -- GILD: $140.2B vs. GSK: $79.1B
GILD [@Pharmaceuticals: Major] is valued at $140.2B. GSK’s [@Pharmaceuticals: Major] market capitalization is $79.1B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $661.43B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • GILD’s FA Score: 3 green, 2 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, GSK is a better buy in the long-term than GILD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 3 TA indicator(s) are bullish while GSK’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 3 bullish, 5 bearish.
  • GSK’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GILD is a better buy in the short-term than GSK.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а -0.82% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.38% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.55%. For the same industry, the average monthly price growth was +1.88%, and the average quarterly price growth was +9.40%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

GSK is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.55% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($140B) has a higher market cap than GSK($79.1B). GILD has higher P/E ratio than GSK: GILD (22.42) vs GSK (17.78). GILD YTD gains are higher at: 24.056 vs. GSK (20.329).
GILDGSKGILD / GSK
Capitalization140B79.1B177%
EBITDA11BN/A-
Gain YTD24.05620.329118%
P/E Ratio22.4217.78126%
Revenue28.9BN/A-
Total Cash5.21BN/A-
Total Debt24.9BN/A-
FUNDAMENTALS RATINGS
GILD vs GSK: Fundamental Ratings
GILD
GSK
OUTLOOK RATING
1..100
6022
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
1465
SMR RATING
1..100
2940
PRICE GROWTH RATING
1..100
5157
P/E GROWTH RATING
1..100
9928
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (6) in the Pharmaceuticals Major industry is in the same range as GILD (15) in the Biotechnology industry. This means that GSK’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (14) in the Biotechnology industry is somewhat better than the same rating for GSK (65) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than GSK’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is in the same range as GSK (40) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.

GILD's Price Growth Rating (51) in the Biotechnology industry is in the same range as GSK (57) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (99) in the Biotechnology industry. This means that GSK’s stock grew significantly faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDGSK
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
46%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
50%
Momentum
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
47%
MACD
ODDS (%)
Bearish Trend 1 day ago
35%
Bearish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
51%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
45%
Bullish Trend 1 day ago
53%
Advances
ODDS (%)
Bullish Trend 24 days ago
59%
Bullish Trend 8 days ago
58%
Declines
ODDS (%)
Bearish Trend 7 days ago
48%
Bearish Trend 29 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
49%
Aroon
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
FLUX.X0.2028270.002761
+1.38%
Flux cryptocurrency
BLUR.X0.0768430.000858
+1.13%
Blur cryptocurrency
MITH.X0.0001880.000001
+0.47%
Mithril cryptocurrency
BONK.X0.000021N/A
-0.08%
Bonk cryptocurrency
GFT.X0.010358-0.012446
-54.58%
Gifto cryptocurrency

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.25%
BMY - GILD
48%
Loosely correlated
+0.19%
GSK - GILD
43%
Loosely correlated
+1.03%
BIIB - GILD
40%
Loosely correlated
+1.43%
AMGN - GILD
40%
Loosely correlated
-1.07%
NVS - GILD
40%
Loosely correlated
+1.26%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with AZN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+1.03%
AZN - GSK
62%
Loosely correlated
+2.39%
PFE - GSK
56%
Loosely correlated
-0.76%
SNY - GSK
53%
Loosely correlated
+0.63%
JNJ - GSK
50%
Loosely correlated
-0.03%
BIIB - GSK
44%
Loosely correlated
+1.43%
More